مجله جهانی جراحی پلاستیک
مجله جهانی جراحی پلاستیک
سه شنبه 13 آبان 1404
[Archive]
چکیده: (55 مشاهده)
Semaglutide, a once-weekly GLP-1 receptor agonist, has emerged as a promising therapeutic option for individuals struggling with obesity and type 2 diabetes mellitus (T2DM). Its ability to induce weight loss, reduce appetite, and improve glycemic control has led to its increasing utilization in clinical practice. Semaglutide works by mimicking the action of endogenous GLP-1, leading to enhanced insulin secretion, decreased glucagon secretion, and delayed gastric emptying
نوع مطالعه: نامه به سردبیر |
موضوع مقاله:
تخصصي
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
